Since the activation of FA receptors such as GPR40 expressed on pancreatic β-cells by specific agonists increases the rate of insulin secretion, GPR40 agonists have been investigated as a promising new therapeutic class for type 2 diabetes mellitus. The gene discussed is FFAR1; the disease is diabetes mellitus.